---
title: 'Associate Director, Strategic Insights at Attovia Therapeutics'
canonical: 'https://feeny.ai/job/associate-director-strategic-insights-attovia-therapeutics-san-carlos-668dcheeceaw'
type: 'job'
last_seen: '2026-11-06'
---

# Associate Director, Strategic Insights at Attovia Therapeutics

- **Company:** Attovia Therapeutics
- **Location:** San Carlos, CA
- **Compensation:** $203k–$247k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-09-25
- **Last confirmed live:** 2026-11-06
- **Apply:** https://jobs.lever.co/attovia-therapeutics/5a401d7c-147e-4b62-b957-d1fbc6097e04

## Job description

Reporting to the Head of Strategy & Corporate Development, the Associate Director, Strategic Insights will serve as an analytical engine for Attovia Therapeutics, Inc. The role spans competitive intelligence (CI), commercial assessment and forecasting, cross-functional strategic initiatives, etc., with priorities shifting based on the company’s needs in a given quarter. Attovia is advancing multiple programs in a public company operating environment while building the infrastructure that will carry the portfolio toward later-stage development and commercialization. The person in this seat will work across that agenda, leading CI capture and synthesis while supporting opportunity assessment, indication and portfolio decisions, and materials prepared for executives and external audiences. This is a hands-on role in a lean organization, with direct exposure to company leaders and the strategic questions the company is actively working through.

## Key Responsibilities

- Lead the capture and delivery of CI spanning competitor programs, targets, and modalities, drawing on congresses, publications, trial registries, regulatory actions, company disclosures, and analyst commentary, and serve as the company's internal reference point on competitor pipelines, trial designs, data readouts, and disclosed strategy
- Translate competitive developments and broader industry trends in immunology into implications for portfolio strategy, indication sequencing, clinical development benchmarking, and partnering posture, and carry those implications through to actionable recommendations
- Own the assumption base underlying commercial forecasts across new and existing indications, working with company leadership and external consultants
- Own the use of AI and LLM tooling for CI, identifying and applying opportunities to improve information capture, structuring, and searchability of the knowledge base
- Design and guide primary research across KOL/HCP, payor, and patient audiences, and secondary research across analyst reports, publications, claims data, etc.
- Support company leadership on high-priority cross-functional initiatives and on external facing materials for partners, investors, analysts, etc.

## Qualifications

- Strong scientific foundation in molecular/cellular biology, with the ability to read primary literature, interpret discovery/preclinical and clinical trial data, and hold technical discussions
- An advanced degree (PhD, MD) with 4+ years of experience across a strategy and/or insights function at a therapeutics company combined with experience at a top-tier life sciences strategy consulting firm, venture capital firm, or life sciences equity research group
- Demonstrated experience across competitive positioning, market sizing, revenue forecasting, and due diligence
- Qualitative and quantitative market research capability, with the financial modeling skill to build the underlying analyses and the storytelling judgment to distill them into clear presentation materials with a defensible narrative
- Demonstrated proficiency with AI and LLM tools to accelerate research and analysis workflows, and strong interest in building or deploying custom tools to enhance how a function operates
- Clear and concise written and verbal communication, adaptable to relevant stakeholder audiences (e.g., executives, investors, KOLs, scientists)
- Comfort operating across multiple functions and workstreams at once, with the project management discipline to hold deadlines through ambiguity
- Based in or relocating to the San Francisco Bay Area
- Ability and willingness to travel up to 10% as required, including attendance at scientific and medical congresses

## About Attovia

Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.  Our product candidates are internally discovered using our proprietary ATTOBODY™ platform, an evolution-driven, high-throughput biologics platform that enables the rapid discovery and creation of diverse biparatopic complex biologics.  Our pipeline spans chronic pruritic diseases, inflammatory skin diseases, inflammatory bowel disease, and other immune-mediated conditions.

Our values define how we make decisions, work with one another, and pursue our mission:

- Integrity: We put patients first, uphold the highest ethical standards, and communicate with honesty and transparency
- Learning & Growth: We ask questions, challenge the status quo, seek and provide constructive feedback, and invest in the development of ourselves and others
- Drive for Excellence: We set ambitious goals, take ownership, honor our commitments, move with urgency, and deliver rigorous, high-quality, and data-driven work
- Innovation: We pursue transformative science, think creatively, and do more with less through resourcefulness and continuous improvement
- Teamwork & Collaboration: We communicate openly, debate constructively, mentor and learn from one another, and recognize that our strongest results come from working together

We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace.

Attovia is located in San Carlos, CA.

Attovia is an equal opportunity employer. We consider all qualified applicants for employment without regard to race, color, ancestry, national origin, religion or creed, age, sex, pregnancy, childbirth, breastfeeding or related medical conditions, sexual orientation, gender, gender identity or gender expression, marital status, medical condition, genetic information, physical or mental disability, military or veteran status, reproductive health decision-making, or any other characteristic protected by applicable federal, state, or local law.

Learn more about Attovia: [www.attovia.com](https://www.attovia.com)

Notice to Employment Agencies The Attovia talent acquisition program is managed through internal resources, and unsolicited referrals and resumes are not accepted from employment agencies, unless advance written authorization is granted from the Human Resources department. Attovia shall not be liable for any fees arising from any unsolicited or unauthorized candidate information received relative to position vacancies.

## About Attovia Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY biparatopic biologics platform.
- **Entity Type**: Private (S-1 filed for IPO)
- **Headquarters**: San Carlos, California, USA
- **Founded**: 2023
- **Founders**: Founded by a group of investors including Alamar Biosciences, Inc. (individual founders not publicly named)

## Core Business
- **Primary industry/industries**: Biopharmaceuticals, immune-mediated diseases (dermatology, gastroenterology/IBD, respiratory)
- **Target customers**: B2B (potential partnerships with larger pharma); ultimately patients with high unmet medical need
- **Mission or purpose statement**: To develop new and improved treatments for patients in need by combining scientific curiosity with impactful change, leveraging the ATTOBODY platform to design novel complex biologics.

## Products & Services
- **ATTOBODY Platform**: Proprietary evolution-driven, high-throughput discovery platform that creates biparatopic (two VHH domains) biologics with ultra-high affinity, modularity, and the ability to target two, three, or four disease-driving pathways in a single molecule. Designed for rapid candidate generation and de-risked development.
- **ATTO-1310**: Monospecific ATTOBODY targeting IL-31. Completed Phase 1 clinical trial dosing in healthy volunteers and patients (Q1 2026). Indications: chronic pruritus, atopic dermatitis, chronic pruritus of unknown origin, cholestatic pruritus, CKD-associated pruritus.
- **ATTO-2306**: Bispecific ATTOBODY targeting IL-13 and IL-31. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory skin diseases (atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis).
- **ATTO-1091**: Trispecific ATTOBODY-based Fc-fusion protein targeting TL1A, IL-23p19, and integrin α4β7. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory bowel disease (ulcerative colitis, Crohn’s disease).
- **Early-stage pipeline (ATTO-006, ATTO-007, ATTO-008)**: Pre-discovery programs targeting T<sub>RM</sub> survival, immune cell survival, and multi-alarmin blockade for rheumatology, IBD, respiratory (asthma, COPD).

## Market Standing
- **Valuation/Market Cap**: Not disclosed (private; S-1 filed indicates intent to raise capital via IPO)
- **Key Metric**: Total funding not publicly disclosed; S-1 filing represents first public financial disclosure. The company is pre-revenue (clinical-stage).
- **Notable Investors/Partners**: Alamar Biosciences (in-licensor of ATTOBODY platform). Additional founding investors not named in public filings.
- **Growth Signals**: Completed Phase 1 for lead candidate ATTO-1310 within ~2 years of founding; headcount grew 35.9% year-over-year to ~40 employees; pipeline expanding into three therapeutic areas with three candidates in IND-enabling studies.

## Competitive Advantages
- **ATTOBODY platform differentiator**: Biparatopic binding enables ultra-high affinity and potency, tunable pharmacokinetics, and modular design for multispecifics (bispecifics, trispecifics, conditional “AND” gate biologics).
- **Speed of discovery**: Evolution-based high-throughput screening allows rapid nomination of multiple candidates (three within first two years).
- **Targeting clinically validated pathways**: Focus on pathways with proven commercial and clinical precedent (IL-31, IL-13, TL1A, IL-23, integrin α4β7), reducing biological risk.
- **Robust drug-like properties**: ATTOBODIES exhibit IgG-like stability and developability, potentially enabling infrequent dosing.

## Strategic Focus
- Advance ATTO-1310 through clinical development for pruritus and atopic dermatitis.
- Progress ATTO-2306 and ATTO-1091 into Phase 1 trials in 2027.
- Expand early-stage pipeline into respiratory and additional inflammatory indications.
- Leverage platform to create next-generation complex biologics that improve upon current standards of care.
- Execute IPO to fund pipeline advancement and platform expansion.

## Why Work Here
- **Culture**: Values-driven environment emphasizing integrity, continuous learning, drive for excellence, innovation, and teamwork. Described as a community of passionate scientists, inspiring leaders, and visionary executives.
- **Benefits**: Comprehensive medical/dental/vision with company premium contributions, FSA/HSA, competitive PTO and sick leave, supplemental parental leave, commute assistance, 401(k) with employer match (immediate vesting), equity grants, educational assistance, and mentorship program.
- **Work environment**: Likely on-site in San Carlos, CA (no explicit remote/hybrid policy stated). Small but rapidly growing team (~40 employees) with a flat, collaborative structure.
- **Engineering/Research culture**: High autonomy, data-driven decision-making, and focus on transformative science. Employees are encouraged to push boundaries and drive progress.

## Sources
1. [linkedin.com](https://linkedin.com/company/attovia-therapeutics) – Employee data, executives, growth
2. [attovia.com](https://www.attovia.com/careers/) – Careers page, culture, benefits
3. [attovia.com](https://www.attovia.com/pipeline/) – Pipeline overview, platform description
4. [sec.gov](https://www.sec.gov/Archives/edgar/data/2058707/000119312526303256/d40469ds1.htm) – S-1 filing, business description, financials
5. [cbinsights.com](https://www.cbinsights.com/company/attovia-therapeutics) – Profile summary, founding year, headquarters

## Other roles at Attovia Therapeutics

- [Director, CMC Management](https://feeny.ai/job/director-cmc-management-attovia-therapeutics-san-carlos-7k9mpk16fpbm) — San Carlos, CA